CDK Cyclin-dependent kinase

Inhibitors

Cat.No.	Name	Information
M1806	PD 0332991 HCL	PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc.
M1974	Roscovitine (Seliciclib)	Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
M1764	PF-477736	PF-477736 is a selective checkpoint kinase 1 (Chk1) inhibitor with Ki values of 0.49 nM and 47 nM for CHK1 and CHK2 respectively.
M2112	LY2835219 mesylate	LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively.
M1807	SCH727965 (dinaciclib)	SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively.
M13619	YKL-5-124 TFA	YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively.
M13618	XL413 hydrochloride	XL413 (BMS-863233) hydrochloride is a potent, selective and ATP competitive inhibitor of Cdc7, with an IC50 of 3.4 nM, and also shows potent effect with IC50s of 215, 42 nM on CK2, PIM1, respectively, and an EC50 of 118 nM on pMCM.
M13617	THZ1 Hydrochloride	THZ1 Hydrochloride is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM. THZ1 Hydrochloride also inhibits the closely related kinases CDK12 and CDK13 and downregulates MYC expression.
M13616	TG003	TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC50 values of 20 and 15 nM, respectively.
M13615	Simurosertib	Simurosertib (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of <0.3 nM. Simurosertib has anti-cancer activity.
M13614	Senexin A	Senexin A is a CDK8 inhibitor with an IC50 of 280 nM.
M13613	SEL120-34A monohydrochloride	SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a K_d of 3 nM for CDK8.
M13612	Samuraciclib hydrochloride hydrate	Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC₅₀ of 41 nM.
M13611	RGB-286638 free base	RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.
M13610	PHA-767491 hydrochloride	PHA-767491 hydrochloride is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively.
M13609	ON-013100	ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression.
M13608	NG 52	NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC₅₀s of 7 μM and 2 μM, respectively.
M13607	Ribociclib succinate hydrate	Ribociclib succinate hydrate (LEE011 succinate hydrate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
M13606	Ribociclib hydrochloride	Ribociclib hydrochloride (LEE011 hydrochloride) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
M13605	AUZ 454	AUZ 454 (K03861) is a type II CDK2 inhibitor with K_d of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.
M13604	Lerociclib dihydrochloride	Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC₅₀s of 1 nM and 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.
M13603	(E/Z)-Zotiraciclib hydrochloride	(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, JAK2, and FLT3 inhibitor.
M13602	Abemaciclib metabolite M18 hydrochloride	Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib , is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.
M13601	CDK9-IN-2	CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC₅₀ of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.
M13600	Abemaciclib metabolite M20	Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor for the treatment of cancer.

Signaling Pathways

Product Type

CDK Cyclin-dependent kinase

Get to Know Us

Customer Support

Resources

Contact Us